词条 | Antisense therapy |
释义 |
This synthesized nucleic acid is termed an "anti-sense" oligonucleotide (ASN) because its base sequence is complementary to the gene's messenger RNA (mRNA), which is called the "sense" sequence (so that a sense segment of mRNA " 5'-AAGGUC-3' " would be blocked by the anti-sense mRNA segment " 3'-UUCCAG-5' "). Antisense oligonucleotides have been researched as potential drugs[2][3][4] for diseases such as cancers (including lung cancer, colorectal carcinoma, pancreatic carcinoma, malignant glioma and malignant melanoma), diabetes, amyotrophic lateral sclerosis (ALS), Duchenne muscular dystrophy, spinal muscular atrophy, Ataxia-telangiectasia (in vitro) and diseases such as asthma, arthritis and pouchitis with an inflammatory component. As of 2016, several antisense drugs have been approved by the U.S. Food and Drug Administration (FDA): fomivirsen as a treatment for cytomegalovirus retinitis, mipomersen for homozygous familial hypercholesterolemia, eteplirsen for Duchenne muscular dystrophy, and nusinersen for spinal muscular atrophy. Example antisense therapiesAs of 2012, some 40 antisense oligonucleotides and siRNAs were in clinical trials, including over 20 in advanced clinical trials (Phase II or III).[5][6] CancerAlso in 2006, German physicians reported on a dose-escalation study for the compound AP 12009 (a phosphorothioate antisense oligodeoxynucleotide specific for the mRNA of human transforming growth factor TGF-beta2) in patients with high grade gliomas. At the time of the report, the median overall survival had not been obtained and the authors hinted at a potential cure.[7] Cytomegalovirus retinitisFomivirsen (marketed as Vitravene), was approved by the U.S. FDA in Aug 1998 as a treatment for cytomegalovirus retinitis. Familial hypercholesterolemiaIn January 2013 mipomersen (marketed as Kynamro) was approved by the FDA for the treatment of homozygous familial hypercholesterolemia.[8][9] Hemorrhagic fever virusesIn early 2006, scientists studying the Ebola hemorrhagic fever virus at USAMRIID announced a 75% recovery rate after infecting four rhesus monkeys and then treating them with an antisense Morpholino drug developed by Sarepta Therapeutics (formerly named AVI BioPharma), a U.S. biotechnology firm.[10] The usual mortality rate for monkeys infected with Ebola virus is 100%. In late 2008, AVI BioPharma successfully filed Investigational New Drug (IND) applications with the FDA for its two lead products for Marburg and Ebola viruses. These drugs, AVI-6002[11] and AVI-6003 are novel analogs based on AVI's PMO antisense chemistry in which anti-viral potency is enhanced by the addition of positively charged components to the morpholino oligomer chain. Preclinical results of AVI-6002 and AVI-6003 demonstrated reproducible and high rates of survival in non-human primates challenged with a lethal infection of the Ebola and Marburg viruses, respectively.[12] HIV/AIDSStarting in 2004, researchers in the US have been conducting research on using antisense technology to combat HIV.[13] In February 2010 researchers reported success in reducing HIV viral load using patient T-cells which had been harvested, modified with an RNA antisense strand to the HIV viral envelope protein, and re-infused into the patient during a planned lapse in retroviral drug therapy.[14] Spinal muscular atrophyIn 2004, development of an antisense therapy for spinal muscular atrophy was started. Over the following years, an antisense oligonucleotide later named nusinersen was developed by Ionis Pharmaceuticals under a licensing agreement with Biogen. In December 2016, nusinersen received regulatory approval from FDA for use to treat spinal muscular atrophy.[15][16] Duchenne muscular dystrophyIn September 2016 eteplirsen, a Morpholino oligo, received FDA approval for the treatment of Duchenne muscular dystrophy. HypertriglyceridemiaVolanesorsen is in phase 3 clinical trials for treating hypertriglyceridemia as of December 2016. DeliveryBecause nucleases that cleave the phosphodiester linkage in DNA are expressed in almost every cell, unmodified DNA molecules are generally degraded before they reach their targets. Therefore, antisense drug candidate molecules are generally modified during the drug discovery phase of their development.[17][18] Additionally, most targets of antisense are located inside cells, and getting nucleic acids across cell membranes is also difficult. Therefore, most clinical candidates have modified DNA "backbones", or the nucleobase or sugar moieties of the nucleotides are altered. Additionally, other molecules may be conjugated to antisense molecules in order to improve their ability to target certain cells or to cross barriers like cell membranes or the blood brain barrier.[17] See also
References1. ^{{cite journal | last = Morcos | first = PA | year = 2007 | title = Achieving targeted and quantifiable alteration of mRNA splicing with Morpholino oligos | journal = Biochem Biophys Res Commun | volume = 358 | issue = 2 | pages = 521–7 | pmid = 17493584 |doi=10.1016/j.bbrc.2007.04.172}} 2. ^Weiss, B. (ed.): Antisense Oligodeoxynucleotides and Antisense RNA : Novel Pharmacological and Therapeutic Agents, CRC Press, Boca Raton, FL, 1997. {{ISBN|0849385520}} {{ISBN|9780849385520}} 3. ^Weiss, B; Davidkova, G; Zhou, LW (March 1999). "Antisense RNA gene therapy for studying and modulating biological processes.". Cellular and molecular life sciences : CMLS. 55 (3): 334–58. {{doi|10.1007/s000180050296}}. {{PMID|10228554}}. 4. ^{{cite book|last1=Goodchild|first1=J|title=Therapeutic oligonucleotides.|journal=Methods in Molecular Biology|date=2011|volume=764|pages=1–15|pmid=21748630|doi=10.1007/978-1-61779-188-8_1|isbn=978-1-61779-187-1}} 5. ^{{cite journal|title=RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform|author=Bennett, C.F.|author2=Swayze, E.E.|journal=Annu. Rev. Pharmacol. Toxicol.|year=2010|volume=50|pages=259–293|doi=10.1146/annurev.pharmtox.010909.105654|pmid=20055705}} 6. ^{{cite journal|title=Silencing Disease Genes in the Laboratory and in the Clinic|author=Watts, J.K.|author2=Corey, D.R.|journal=J. Pathol.|year=2012|volume=226|issue=2|pages=365–379|doi=10.1002/path.2993 |pmid=22069063|pmc=3916955}} 7. ^Results of G004, a phase IIb actively controlled clinical trial with the TGF-b2 targeted compound AP 12009 for recurrent anaplastic astrocytoma - Hau et al. 24 (18 Supplement): 1566 - ASCO Meeting Abstracts {{webarchive|url=https://archive.is/20120712062953/http://meeting.jco.org/cgi/content/abstract/24/18_suppl/1566 |date=2012-07-12 }} 8. ^Pollack, Andrew (29 January 2013) [https://www.nytimes.com/2013/01/30/business/fda-approves-genetic-drug-to-treat-rare-disease.html F.D.A. Approves Genetic Drug to Treat Rare Disease] The New York Times, Retrieved 31 January 2013 9. ^Staff (29 January 2013) FDA approves new orphan drug Kynamro to treat inherited cholesterol disorder U.S. Food and Drug Administration, Retrieved 31 January 2013 10. ^U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland. News Release: Gene-Specific Ebola Therapies Protect Nonhuman Primates from Lethal Disease. January 13, 2006. {{webarchive |url=https://web.archive.org/web/20070609104434/http://www.usamriid.army.mil/press%20releases/warfield_press_release.pdf |date=June 9, 2007 }} 11. ^{{cite journal |pmid=15194784 |year=2004 |last1=Lu |first1=X |last2=Yu |first2=Q |last3=Binder |first3=GK |last4=Chen |first4=Z |last5=Slepushkina |first5=T|last6=Rossi|first6=J|last7=Dropulic|first7=B|title=Antisense-Mediated Inhibition of Human Immunodeficiency Virus (HIV) Replication by Use of an HIV Type 1-Based Vector Results in Severely Attenuated Mutants Incapable of Developing Resistance |volume=78 |issue=13 |pages=7079–88 |doi=10.1128/JVI.78.13.7079-7088.2004 |pmc=421644 |journal=Journal of Virology}} 12. ^Medical News Today. AVI BioPharma Announces FDA Clears IND Applications For Clinical Trials Of RNA Therapeutic Agents For Treatment Of Ebola And Marburg Viruses. 30 Dec 2008. 13. ^{{cite journal | pmid = 15194784 | doi=10.1128/JVI.78.13.7079-7088.2004 | pmc=421644 | volume=78 | issue=13 | title=Antisense-mediated inhibition of human immunodeficiency virus (HIV) replication by use of an HIV type 1-based vector results in severely attenuated mutants incapable of developing resistance | date=July 2004 | journal=J. Virol. | pages=7079–88 | last1 = Lu | first1 = X | last2 = Yu | first2 = Q | last3 = Binder | first3 = GK | display-authors = et al}} 14. ^[https://www.sciencedaily.com/releases/2010/02/100218191736.htm University of Pennsylvania School of Medicine. "Phase II HIV Gene Therapy Trial Has Encouraging Results." ScienceDaily 19 February 2010.] 15. ^{{cite journal|last1=Wadman|first1=Meredith|title=Updated: FDA approves drug that rescues babies with fatal neurodegenerative disease|journal=Science|date=23 December 2016|url=http://www.sciencemag.org/news/2016/12/novel-drug-rescues-babies-fatal-neurodegenerative-disease}} 16. ^{{Cite news|url=https://www.wsj.com/articles/surprise-drug-approval-is-holiday-gift-for-biogen-1482856447|title=Surprise Drug Approval Is Holiday Gift for Biogen|last=Grant|first=Charley|date=2016-12-27|work=|newspaper=Wall Street Journal|issn=0099-9660|access-date=2016-12-27|via=}} 17. ^1 Bennett CF, Swayze EE. [https://www.ncbi.nlm.nih.gov/pubmed/20055705/ RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform]. Annu Rev Pharmacol Toxicol. 2010;50:259-93. {{doi|10.1146/annurev.pharmtox.010909.105654}}. {{PMID|20055705}} 18. ^Xu L, Anchordoquy T. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3303188/ Drug delivery trends in clinical trials and translational medicine: challenges and opportunities in the delivery of nucleic acid-based therapeutics]. J Pharm Sci. 2011 Jan;100(1):38-52. {{doi|10.1002/jps.22243}}. {{PMID|20575003}} External links
4 : Applied genetics|Biotechnology|Gene therapy|Therapeutic gene modulation |
随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识,基本涵盖了大多数领域的百科知识,是一部内容自由、开放的电子版国际百科全书。